Introduction
============

Neuroblastoma is one of the most common extracranial solid tumor in children, which accounts for about 7--10% in children's tumors ([@ref-1]; [@ref-13]; [@ref-17]). Neuroblastoma originates from nerve sympathetic cells and can occur in sympathetic neuronal cells of embryonic neural crest cells. It can arise anywhere along the sympathetic nervous system chain, including the abdomen, adrenal gland, chest, neck, and pelvis, and is often transferred to the parts such as focal lymph node, marrow, skeleton, and liver ([@ref-16]). Early diagnosis of neuroblastoma is difficult, with a high degree of malignancy and easy to metastasis. The cancer mortality rate of neuroblastoma in children is just fall behind leukemia and brain tumors, which accounts for about 11% ([@ref-3]). The prognosis of patients with neuroblastoma is quite variant. The prognosis group of patients with neuroblastoma was classify in to high-risk patients and low-risk patients, which could not only improve the efficacy of high-risk patients, but also reduce the effects of drug complications for surviving patients. Therefore, it is necessary to analyze the prognosis of patients with neuroblastoma.

Clinically, prognostic factors of neuroblastoma include factors such as age of diagnose, International Neuroblastoma Staging System (INSS) stage, *MYCN* status, and tumor histology ([@ref-27]). *MYCN* is a prognostic related gene of neuroblastoma. Approximately 25% of patients presented with *MYCN* gene amplification which was regarded as a biomarker for poor prognosis ([@ref-30]). Levels of DNA ploidy have been found to be one of significant prognostic factors. Patients with DNA aneuploid neuroblastoma died less frequently than those with DNA diploid tumors ([@ref-8]). The INSS staging system is widely used in the clinical staging of primary organs and metastases in neuroblastoma. In addition, the children's oncology group (COG) risk group ([@ref-14]) is a commonly used system for therapeutic decision-making reference, which dividing patients with neuroblastoma into low-risk, intermediate-risk, and high-risk groups. The COG risk group imports factors such as INSS stage, age of diagnose, *MYCN*, tumor histology, and DNA ploidy status.

The therapeutically applicable research to generate effective treatment (TARGET) database is a project containing experimental and clinical materials of a number of caners of children. TARGET project is affiliated to the Center for Cancer Genomics of the National Cancer Institute and is aimed to use data to guide the development of effective and less toxic therapies. In this study, we collected and analyzed the information of child neuroblastoma patients from the TARGET database and explored possible prognostic nomogram for more accurate assessment of the prognosis of patients of children with neuroblastoma.

Materials and Methods
=====================

Data source and eligibility criteria
------------------------------------

We downloaded clinical data of patients with neuroblastoma from the TARGET project database (<https://ocg.cancer.gov/>) ([@ref-19]; [@ref-31]). The inclusion criterion was that the patients were diagnosed with neuroblastoma from 1986 to 2012. Exclusion criteria were as follows: unknown age of diagnosis, uncertain gender, undetermined race, uncertain INSS stage, uncertain *MYCN* amplification status, unknown DNA ploidy status, undetermined tumor histology, unclear pathological histology results, uncertain mitosis-karyorrhexis index (MKI), unknown COG risk group, and the age is over 18 years old.

The categorical measurements were described as counts and percentages, and the continuous measurements were presented as mean and range. The *t-*test was used to continuous measurements, while the Chi-square for compare ones. *P* \< 0.05 was considered statistically significant. Overall survival (OS) were used as primary end points. OS was defined as the interval from the time of diagnosis to death or last follow-up regardless of death cause. Optimal cutoff value of age was determined by "survminer" package of R software ([@ref-32]). The nomogram was built with potential risk factors based on COX regression analysis in the training cohort. concordance index (C-index) was used to estimate predictive performance of the nomogram. The larger the C-index, the more accurate the model prediction. The C-index of the nomogram was compared with the C-index of INSS staging system, tumor histology and COG risk group. Calibration plots were used to compare the observed and predicted probabilities for the nomogram. The precision of the 3-year and 5-year survival of the nomograms was evaluated by the area under ROC (Receiver operating characteristic) curve (AUC). The flow diagram is shown in [Fig. S1](#supp-4){ref-type="supplementary-material"}.

Results
=======

Patient characteristics
-----------------------

The original cohort with a total of 1,119 patients was involved. A total of 757 patients complied with inclusion criteria. The median OS was 1,668 days (range 10--5,216 days). The 3-year and 5-year OS rates were 75.54% and 44.39%, respectively. We used R software (3.5.2) as our statistical analysis tool. Optimal cutoff value of age of diagnosis was 520 days. 70% of all patients were randomly selected to form the training cohort for the construction of nomogram while the rest 30% patients served as the validation cohort. The demographics and clinicopathologic characteristics of training cohort (*n* = 532), validation cohort (*n* = 225) and all patients (*n* = 757) are shown in [Table 1](#table-1){ref-type="table"}.
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###### Demographics and clinicopathologic characteristics of patients with neuroblastoma of children.

![](peerj-07-7316-g005)

  Demographics or characteristic               Training cohort *n* = 532 (%)   Validation cohort *n* = 225 (%)   *P-*value
  -------------------------------------------- ------------------------------- --------------------------------- -----------
  **Sex**                                                                                                        0.976
   Female                                      224 (42.11)                     95 (42.22)                        
   Male                                        308 (57.89)                     130 (57.78)                       
  **Age, days**                                                                                                  0.719
   ≤520                                        175 (32.89)                     71 (31.56)                        
   \>520                                       357 (67.11)                     154 (68.44)                       
  **Race**                                                                                                       0.960
   White                                       443 (83.27)                     183 (81.33)                       
   Native Hawaiian or other Pacific Islander   6 (1.13)                        2 (0.89)                          
   Black or African American                   66 (12.41)                      32 (14.22)                        
   Asian                                       15 (2.82)                       7 (3.11)                          
   American Indian or Alaska Native            2 (0.28)                        1 (0.44)                          
  **INSS stage**                                                                                                 0.911
   Stage 1                                     49 (9.21)                       23 (10.22)                        
   Stage 2                                     37 (6.95)                       18 (8.00)                         
   Stage 3                                     53 (9.96)                       23 (10.22)                        
   Stage 4                                     393 (73.87)                     161 (71.56)                       
  ***MYCN* status**                                                                                              0.551
  ** **Not amplified                           378 (71.05)                     155 (68.89)                       
   Amplified                                   154 (28.95)                     70 (31.11)                        
  **Ploidy**                                                                                                     0.864
   Diploid (DI=1)                              195 (36.65)                     81 (36.00)                        
   Hyperdiploid (DI\>1)                        337 (63.35)                     144 (64.00)                       
  **MKI**                                                                                                        0.819
   Low                                         214 (40.23)                     85 (37.78)                        
   Intermediate                                158 (29.7)                      70 (31.11)                        
   High                                        160 (30.08)                     70 (31.11)                        
  **Histology**                                                                                                  0.514
   Unfavorable                                 368 (69.17)                     161 (71.56)                       
   Favorable                                   164 (30.83)                     64 (28.44)                        
  **COG risk group**                                                                                             0.155
   Low risk                                    105 (19.74)                     34 (15.11)                        
   Intermediate risk                           58 (10.90)                      33 (14.67)                        
   High risk                                   369 (69.36)                     158 (70.22)                       

Prognostic factors of OS in the training cohort
-----------------------------------------------

To analyze prognostic factors of OS, we used the univariate analysis and multivariate analysis. As shown in [Table 2](#table-2){ref-type="table"}, univariate analysis showed that age of diagnosis (\>520 days), race of American Indian or Alaska Native, stage 4 in INSS, *MYCN* status, DNA ploidy, high MKI were associated with OS. Meanwhile, multivariate analysis showed age of diagnosis (\>520 days), stage 4 in INSS and DNA ploidy were independent risk factors of OS.
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###### Univariate analysis and multivariate analysis in the training cohort.
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  Demographics or characteristic               No.   Univariate analysis         Multivariate analysis                               
  -------------------------------------------- ----- --------------------------- ----------------------- --------------------------- -------
  **Sex**                                                                                                                            
   Female                                      224                                                                                   
   Male                                        308   0.916 \[0.682--1.229\]      0.558                   0.798 \[0.588--1.084\]      0.148
  **Age, days**                                                                                                                      
   ≤520                                        175                                                                                   
   \>520                                       357   4.720 \[2.963--7.519\]      0.000                   1.750 \[1.041--2.944\]      0.035
  **Race**                                                                                                                           
   White                                       443                                                                                   
   Native Hawaiian or other Pacific Islander   6     1.126 \[0.279--4.548\]      0.868                   1.122 \[0.273--4.609\]      0.873
   Black or African American                   66    0.912 \[0.578--1.439\]      0.691                   0.787 \[0.495--1.251\]      0.311
   Asian                                       15    0.801 \[0.297--2.162\]      0.662                   0.711 \[0.258--1.958\]      0.509
   American Indian or Alaska Native            2     5.639 \[1.393--22.829\]     0.015                   3.486 \[0.829--14.666\]     0.088
  **INSS Stage**                                                                                                                     
   Stage 1                                     49                                                                                    
   Stage 2                                     37    3.061 \[0.277--33.779\]     0.361                   2.148 \[0.191--24.170\]     0.536
   Stage 3                                     53    4.679 \[0.523--41.901\]     0.168                   2.926 \[0.317--26.993\]     0.344
   Stage 4                                     354   34.724 \[4.860--248.092\]   0.000                   17.073 \[2.257--129.178\]   0.006
   Stage 4S                                    39    4.751 \[0.494--45.708\]     0.177                   4.633 \[0.481--44.638\]     0.185
  ***MYCN* status**                                                                                                                  
   Not Amplified                               378                                                                                   
   Amplified                                   154   1.935 \[1.434--2.612\]      0.000                   1.226 \[0.843--1.782\]      0.286
  **Ploidy**                                                                                                                         
   Diploid (DI = 1)                            195                                                                                   
   Hyperdiploid (DI \> 1)                      337   0.410 \[0.306--0.550\]      0.000                   0.641 \[0.470--0.876\]      0.005
  **MKI**                                                                                                                            
   Low                                         214                                                                                   
   Intermediate                                158   1.385 \[0.950--2.021\]      0.090                   0.884 \[0.595--1.314\]      0.543
   High                                        160   2.176 \[1.532--3.090\]      0.000                   1.094 \[0.716--1.673\]      0.677

Prognostic nomogram for OS
--------------------------

We integrated the factors including age of diagnose, INSS stage and DNA ploidy to form the prognostic nomogram ([Fig. 1](#fig-1){ref-type="fig"}). The C-index of the nomogram was 0.704 (95% CI \[0.686--0.722\]) in the training cohort while the C-index in the validation cohort was 0.672 (95% CI \[0.644--0.700\]). As shown in [Fig. 2](#fig-2){ref-type="fig"}, the AUC values of ROC curves for 3-year OS and 5-year OS in the training cohort were 0.732 and 0.772, respectively. Besides, the AUC values of ROC curve for 3-year OS and 5-year OS in the validation cohort were 0.703 and 0.743, respectively. The calibration plots for the probability of 3-year OS and 5-year OS indicated no apparent departure form ideal line with optimal agreement between prediction by nomogram and observation in both training cohort and validation cohort.

![Nomogram to predict the probability of 3-year OS and 5-year OS.](peerj-07-7316-g001){#fig-1}

![ROC curves and calibration plots of the nomogram in training and validation cohorts.\
(A) ROC curves for discrimination in the training set. (B) Calibration plot of observed and predicted probabilities for the nomogram in the training set at 3 years. (C) Calibration plot of observed and predicted probabilities for the nomogram in the training set at 5 years. (D) ROC curves for discrimination in the validation set. (E) Calibration plot of observed and predicted probabilities for the nomogram in the validation set at 3 years. (F) Calibration plot of observed and predicted probabilities for the nomogram in the validation set at 5 years.](peerj-07-7316-g002){#fig-2}

We also analyzed the ROC curves and calculated C-index for the prognostic ability of INSS staging system, tumor histology, and COG risk group. As shown in [Fig. 3](#fig-3){ref-type="fig"}, the AUC values of ROC curves for 3-year OS and 5-year OS in the training cohort were 0.679 and 0.732 in INSS staging system, respectively. The AUC values of ROC curves for 3-year OS and 5-year OS in the training cohort were 0.646 and 0.701 in tumor histology system, respectively. The AUC values of ROC curves for 3-year OS and 5-year OS in the training cohort were 0.669 and 0.719 in COG risk group. The C-indexes for INSS staging system, tumor histology and COG risk group were 0.662 (95% CI \[0.648--0.676\]), 0.637 (95% CI \[0.622--0.652\]) and 0.651 (95% CI \[0.637--0.665\]) in the training cohort, respectively. While C-indexes for INSS staging system, tumor histology and COG risk group were 0.649 (95% CI \[0.630--0.668\]), 0.641 (95% CI \[0.621--0.661) and 0.663 (95% CI \[0.645--0.681\]) in the validation cohort, respectively.

![ROC curves.\
ROC curves of (A) INSS staging system, (B) histology groups of Shimada system, and (C) COG staging system in training cohort.](peerj-07-7316-g003){#fig-3}

Survival curves for prognostic factors
--------------------------------------

At last, we analyzed the correlation between the prognostic factors in the nomogram and the OS, and drew the survival curves ([Fig. 4](#fig-4){ref-type="fig"}). The description of risk levels in the training cohort is shown in [Table S3](#supp-3){ref-type="supplementary-material"}. We found that age, race, INSS staging system, *MYCN*, DNA ploidy status, MKI, and calculated risk scores were associated with overall survival.

![Kaplan--Meier survival curves of the training cohort.\
(A) Kaplan--Meier survival curves of gender. (B) Kaplan--Meier survival curves of age. (C) Kaplan--Meier survival curves of race. (D) Kaplan--Meier survival curves INSS. (E) Kaplan--Meier survival curves of *MYCN*. (F) Kaplan--Meier survival curves Ploidy. (G) Kaplan--Meier survival curves MKI. (H) Kaplan--Meier survival curves risk score.](peerj-07-7316-g004){#fig-4}

Clinical use of the nomogram
----------------------------

For example, one case of the cohort whose age was 1,758 days (\>520 days) was identified as stage 4 in INSS and hyperdiploid status. The estimated point was about 18 + 100 + 0 =118. The estimated 3-year survival rate and 5-year survival rate was about 80% and 72%, respectively. Actually, this patient died at the age of 2,846 days (7.80 years).

Discussion
==========

Our study found that age of diagnosis (\>520 days), stage 4 in INSS and DNA ploidy were independent prognostic risk factors for neuroblastoma in children. Then the prognostic nomogram was constructed based on age of diagnose, INSS stage, and DNA ploidy status to predict 3-year OS and 5-year OS. The nomogram can provide a relatively accurate estimate of the prognosis of patients. There are many reports that the nomogram has higher accuracy than the conventional tumor staging system ([@ref-11]; [@ref-25]; [@ref-23]). The nomogram showed stronger predictive power than the INSS staging system, tumor histology, and COG risk group.

The nomogram is mainly used to predict the relevant conditions of the disease. In terms of tumors, the nomogram is mainly used for prognostic models such as tumor patient mortality, lymph node metastasis, and complications ([@ref-12]; [@ref-26]). The nomogram is a new form of disease risk estimation that can aid clinical decision making ([@ref-4]). Studies based on the Surveillance, Epidemiology, and End Results Program (SEER) database showed that gender had no significant difference in the OS of neuroblastoma in children ([@ref-20]). These results were consistent with our findings. Zhao reported clinical data of 155 children with neuroblastoma under the age of 18. It was found that the patients had 3-year and 5-year overall survival rate of 96.2% and 94.1%, and compared with 12--18 months, 12 month-old-children had a better prognosis. *MYCN* amplification, elevated LDH was associated with poor prognosis ([@ref-29]). Campbell reviewed 4,672 patients with neuroblastoma and found that patients with *MYCN* amplification had lower event-free survival and lower overall survival ([@ref-5]). Moreover, studies had shown that *MYCN* amplification in serum of patients with neuroblastoma was also associated with overall patient survival ([@ref-28]). Neuroblastoma patients with overexpressing *MYCN* and *MYCN* protein had lower survival rates ([@ref-2]; [@ref-24]). In addition to *MYCN* gene abnormalities, deletion of 11q was also associated with prognosis in patients with neuroblastoma ([@ref-6]). Based on the SEER database, it was found that stage 4 disease, unfavorable DNA ploidy, *MYCN* gene amplification decreased the 5-year survival rates ([@ref-7]), while age, tumor location, stage are independent prognostic factors for neuroblastoma ([@ref-10]).

The International Neuroblastoma Staging System staging system is widely used in patients with neuroblastoma, which is also a common prognostic indicator ([@ref-2]; [@ref-21]). The International Neuroblastoma Pathology Classification (INPC) classifies neuroblastoma into the favorable histology (FH) group and the unfavorable histology (UFH) group. The FH group had an earlier onset and a good prognosis, while the UFH group had a poor prognosis ([@ref-18]). The COG risk group was established in 1998 for prognosis of neuroblastoma. Age of diagnose, INSS stage, INPC, *MYCN* status, and DNA ploidy status are included in the COG risk group. After the application of the COG risk group, the survival of patients with neuroblastoma is greatly improved ([@ref-9]).

The optimal cutoff of age in this study was determined by the "survminer" package of R software using maximally selected rank statistics (the P-age curve is shown in [Fig. S2](#supp-5){ref-type="supplementary-material"}). The cutoff was younger than that suggested by [@ref-15] probably because of selection of cases or inclusion criteria.

However, there are also many limitations in this study. For example, the different treatment options of individuals and secondary cancer may influence the effectiveness of model. There are many breakthroughs in the treatment of neuroblastoma in recent years ([@ref-22]), which may also have survival impact affecting the study results. Moreover, adding more updated data to the study can make the results more accurate. Other potential factors such as TERT rearrangements, ATRX mutations, CCND1 amplification may also perform well in prognosis of neuroblastoma. In addition, due to the limitations of the collected case data, the study case cannot include population characteristics in all regions, which may affect the nomogram to reflect all population characteristics.

Conclusion
==========

Analysis of clinical data based on big data is an important source of clinical prognostic indicators. The vast majority of current clinical data analysis is based on the SEER database. The TARGET database is part of the National Cancer Institute project and its clinical data is rarely reported. As we known, we analyzed the primary data of childhood neuroblastoma for the first time. Based on the patients' primary clinical data, the prognostic nomogram of the prognosis of childhood neuroblastoma was established, whose accuracy was higher than the INSS staging system, the INPC, and the COG risk group. Precise estimates of the prognosis of childhood neuroblastoma might help doctors assess the patients' actual condition, select appropriate treatment options, and develop better follow-up plans.
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###### Dataset S1.

Raw data exported from the TARGET database: gender, race, age at diagnosis, INSS stage, MYCN status, ploidy status, MKI status, histology status, and COG risk group.

###### 

Click here for additional data file.
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###### Dataset S2.

Raw data exported from the TARGET database: gender, race, age at diagnosis, INSS stage, MYCN status, ploidy status, MKI status, histology status, and COG risk group.

###### 

Click here for additional data file.
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###### Coefficients for calculating risk score.

###### 

Click here for additional data file.
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###### Flow diagram.

###### 

Click here for additional data file.
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###### Log~10~(*P*) of different cutoff of age.

\(A\) Log~10~(*P*)-age plot. (B) Close-up view of Fig. S2A.

###### 

Click here for additional data file.
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